Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 24,942

Document Document Title
WO/2020/186345A1
The present invention relates to treatment of cancer. In particular, the present invention relates to peptides that bind KDM5C for the treatment of cancer.  
WO/2020/187268A1
The present invention relates to a fusion protein for enhancing gene editing and use thereof. In particular, the invention provides an enhanced fusion protein. The enhanced fusion proteins of the present invention can significantly incre...  
WO/2020/190902A1
Disclosed herein are CAR-T cells with enhanced tumor infiltration. As disclosed herein, infiltrating lymphocytes (T and NK) within tumor tissue are absent of CX3CR1, a key chemokine receptor specific for lymphocytes. Therefore, disclosed...  
WO/2020/187016A1
Provided is a ROBO1 CAR-NK cell carrying suicide gene, a preparation method therefor and application thereof. In order to increase the safety and controllability of CAR-NK therapy, on the basis of the present ROBO1 CAR-NK cell, a suicide...  
WO/2020/142750A3
Genetically modified cells, tissues, and organs for treating or preventing diseases are disclosed. Also disclosed are methods of making the genetically modified cells and non-human animals.  
WO/2020/187270A1
Provided are a fusion protein containing fluorescent protein fragments and uses thereof. The fusion protein according to the present invention has a structure as expressed by (P1-L1)s-A1-(X)n-A2-(L2-P2)t, wherein (X)n or A1-(X)n can prom...  
WO/2020/191281A1
The present invention provides, in various embodiments, electrically conductive protein nanowires (e-PNs) having surface exposed peptides that confer additional sensing capabilities and/or enhance binding to other materials, as well as f...  
WO/2020/181756A1
Provided is a method for improving the biocoupling efficiency between a protein and a nucleic acid based on an α-helix handle. The method comprises designing a handle H-tag carrying an unnatural amino acid, then constructing a fusion re...  
WO/2020/182229A1
Provided are a fusion protein Leading Peptide-DDDDK-GLP-1(7-37) and a method using same to prepare a liraglutide intermediate polypeptide GLP-1 (7-37). The preparation method comprises: constructing an engineering strain that expresses t...  
WO/2020/181846A1
Provided are a cysteine-containing antibody, a drug conjugate and a use thereof. The heavy chain constant region of the antibody is a humanized γ1 chain, and the light chain constant region thereof is a humanized κ chain, wherein amino...  
WO/2020/018732A8
A composition for charactering an internalizing antibody is provided. The composition includes an antibody-binding moiety and a detectable agent.  
WO/2020/185562A1
A novel lantibiotic peptide and a composition comprising the peptide in an antimicrobial effective amount are provided. A method for preparing the composition from a medium into which host cells produce the peptide is also provided. A me...  
WO/2020/047185A9
The present invention includes a composition and method of allosterically potentiating the activity of neurolysin comprising contacting the neurolysin with an amount of a histidine-containing dipeptide that is an allosteric that increase...  
WO/2020/154087A3
Provided are molecular feedback circuits as well as nucleic acids encoding such molecular feedback circuits and cells genetically modified with the subject molecular feedback circuits. Methods of modulating signaling of a signaling pathw...  
WO/2020/086144A3
The disclosure describes methods, compositions, and kits for high throughput DNA assembly reactions in vitro. The disclosure further describes modular CRISPR DNA constructs comprising modular insert DNA parts flanked by cloning tag segme...  
WO/2020/142306A3
Clostridium difficile, reclassified as Clostridioides difficile, is a Gram-positive, spore-forming, anaerobic, and toxin-producing nosocomial pathogen. Since the first description of a C. difficile-associated disease (CDAD)-like case in ...  
WO/2020/178740A1
The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide seq...  
WO/2020/177751A1
Provided is a nucleic acid construct for gene editing, wherein the nucleic acid construct having a specific structure can permit gRNA-directed site-directed mutagenesis of bases in plants.  
WO/2020/178744A1
The present disclosure is directed recombinant T cell receptors capable of binding a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequenc...  
WO/2020/177179A1
The present application belongs to the field of biotechnology, and discloses a genetically modified metastable bovine respiratory syncytial virus fusion precursor F protein, and a coding DNA molecule and application thereof. The present ...  
WO/2020/178738A1
The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide seq...  
WO/2020/177712A1
The present application provides an FGF21 polypeptide, which has one or more of the following properties: stable structure, long half-life, low immunogenicity, high biological activity, and enhanced glucose-lowering and lipid-lowering ac...  
WO/2020/177717A1
The present invention provides a novel bispecific binding molecule and use thereof. The novel bispecific binding molecule-drug conjugate of the present invention comprises: a) a bispecific binding molecule consisting of a first binding p...  
WO/2020/178742A1
The present disclosure is directed recombinant T cell receptors capable of binding an gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequen...  
WO/2020/178743A1
The present disclosure is directed recombinant T cell receptors capable of binding a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequenc...  
WO/2020/177733A1
Provided are a bifunctional fusion protein and pharmaceutical use thereof. Specifically, provided are a bifunctional fusion protein comprising an SIRPγ peptide variant and an anti-human PD-L1 antibody, an SIRPγ peptide variant, and pha...  
WO/2020/178739A1
The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide seq...  
WO/2020/073835A8
The present invention relates to an anti-IL-6 antibody, a pharmaceutical composition or a kit comprising same, and uses thereof.  
WO/2020/175366A1
In the present invention, a cell expresses: a chimeric antigen receptor including a region that binds to a first antigen, a transmembrane domain, and a protease, but not including a cleavage site of the protease; and a chimeric antigen r...  
WO/2020/175660A1
A novel vaccine antigen for preventing respiratory syncytial virus (RSV) infection is produced, which is improved in efficacy and/or safety compared with conventional vaccines each containing only RSV F-protein as an antigen. A vaccine i...  
WO/2020/176718A1
The present invention relates to, inter alia, combinations of compositions which include chimeric proteins that find use in methods for treating disease, such as immunotherapies for cancer and autoimmunity.  
WO/2020/173123A1
The present invention invention belongs to the field of tumor immunotherapy, and specifically provides a new type of replication oncolytic adenovirus AD5 sPD1CD137L having activated immune co-stimulatory signal pathway and blocking immun...  
WO/2020/175502A1
The present invention provides a fusion protein of an antigen-binding protein and a fluorescent protein or a fluorescence-labeled tag protein. The present invention provides a fusion protein of an antigen-binding protein and a fluoresc...  
WO/2020/173403A1
The present invention discloses a ZmWAK-RLK protein related to gray leaf spot resistance, and an encoding gene and application thereof. The present invention sets forth a protein obtained from a maize inbred line Y32, named ZmWAK-RLK, an...  
WO/2020/127377A9
The present invention relates to a bifunctional molecule comprising an anti-PD-1 antibody and IL-7 and its uses.  
WO/2020/173460A1
Disclosed are a full human broad-spectrum neutralizing antibody against respiratory syncytial virus and use thereof. Specifically, disclosed in the present invention are a full human monoclonal antibody 4F1 against a respiratory syncytia...  
WO/2020/174070A1
A genome-editing complex for modifying a target polynucleotide comprising a recombinant β helical protein linked to either one or more molecules of a genome-editing system or a plasmid encoding for one or more molecules of a genome-edit...  
WO/2020/142659A3
Disclosed herein are multi-specific binding polypeptide molecules (e.g., multi-specific antibodies) that can interact with a tumor cell and an immunosuppressive cell. In some embodiments, also described herein are methods for treating on...  
WO/2020/176794A1
Antibody-drug conjugates (ADCs) are described, comprising anti-TM4SF1 antibodies, and antigen-binding fragments thereof. Methods of use of said ADCs are also described.  
WO/2020/171161A1
An objective of the present invention is to develop and provide a self-assembling peptide that is biocompatible and has a controllable sol-gel transition temperature, and to provide a method for causing sol-gel transition of the self-ass...  
WO/2020/168424A1
Nucleic acids encoding rotavirus VP7 fusion proteins and rotavirus-like particle (RLPs) comprising the rotavirus VP7 fusion proteins are provided. Methods for rotavirus VP7 fusion protein and RLP production in plants are also described. ...  
WO/2020/163953A1
Lymphocytes having a suppressed autophagy gene useful in immunotherapy are disclosed. The lymphocytes can express an antigen targeting receptor such as a chimeric antigen receptor (CAR) or endogenous or engineered T-cell receptor to targ...  
WO/2020/113224A3
This invention is directed to chimeric antigen receptors and cells comprising the same, wherein the cells further secrete monoclonal antibodies locally at a tumor site.  
WO/2020/167894A1
The present disclosure provides novel cell permeant polypeptides and pharmaceutical compositions thereof, and methods for using such polypeptides and pharmaceutical compositions for various therapeutic uses. The present disclosure more s...  
WO/2020/168090A1
Methods of increasing or enhancing the efficacy of CAR B cell malignancy treatment regimens using immune effector cells (e.g., T cells, NK cells, CIK cells, macrophages) engineered to express chimeric antigen receptors (CAR(s)) that targ...  
WO/2020/163353A1
The present disclosure generally relates to compositions and methods for treating a disease or condition associated with opening of Cx43 hemichannels in astrocytes or osteocytes, preferably for treating an inflammatory disease or conditi...  
WO/2019/222071A3
The present invention provides a Fluorescence Resonance Energy Transfer (FRET) biosensor that measures the metastatic potential and/or chemoresistance of single living cancer cells, and/or cells associated with fibrogenesis, diabetes, ag...  
WO/2020/162452A1
Provided are: a CAR library used in screening of scFv, which can function in CAR-T cells; and a production method for scFv using the CAR library. The chimera antigen receptor (CAR) library according to the present invention includes nucl...  
WO/2020/163222A1
The present invention is directed to a nucleic acid sequence comprising: (a) a first polynucleotide encoding a chimeric antigen receptor (CAR) fusion protein comprising from the N-terminus to C-terminus: (i) a single-chain variable fragm...  
WO/2020/163529A1
Provided herein are methods and compositions for the prevention and treatment of nonalcoholic steatohepatitis (NASH) by targeting the CD24-Siglec axis.  

Matches 1 - 50 out of 24,942